Pharming Group (NASDAQ:PHAR) Shares Gap Down to $10.00

Pharming Group (NASDAQ:PHAR - Get Free Report) shares gapped down prior to trading on Monday . The stock had previously closed at $10.00, but opened at $9.59. Pharming Group shares last traded at $9.59, with a volume of 396 shares trading hands.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a "buy" rating and set a $37.00 target price on shares of Pharming Group in a research note on Thursday, March 14th.

Pharming Group Trading Down 6.0 %

The firm has a market capitalization of $633.00 million, a price-to-earnings ratio of -58.75 and a beta of 0.20. The stock has a fifty day moving average of $10.51 and a 200-day moving average of $11.32.

Pharming Group (NASDAQ:PHAR - Get Free Report) last issued its quarterly earnings results on Thursday, March 14th. The company reported ($0.03) earnings per share for the quarter, missing analysts' consensus estimates of $0.05 by ($0.08). Pharming Group had a negative net margin of 4.01% and a negative return on equity of 4.61%. The business had revenue of $81.20 million for the quarter, compared to analysts' expectations of $71.83 million. As a group, equities research analysts forecast that Pharming Group will post -0.03 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Pharming Group

A hedge fund recently bought a new stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC purchased a new position in shares of Pharming Group (NASDAQ:PHAR - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 17,710 shares of the company's stock, valued at approximately $202,000. Hedge funds and other institutional investors own 0.03% of the company's stock.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.